Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome and Paradoxical Psoriasis with Secukinumab: A Case Report

Abstract

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic inflammatory disease mainly manifested as skin and osteoarticular lesions. Herein, we describe a female patient with SAPHO syndrome exhibited paradoxical psoriasis and primary palmoplantar pustulosis (PPP) worsened during treatment with adalimumab. We then switched to secukinumab and obtained significant improvement in both skin lesions and osteoarticular pain. These findings suggest that secukinumab might be an appropriate option for patients with SAPHO syndrome who present with TNF-α-inhibitor-induced paradoxical psoriasis.

Keywords:

• SAPHO syndrome
• psoriasis
• adalimumab
• secukinumab

Consent

Written informed consent for publication of the case details and any accompanying images was obtained from the patient. This study was performed according to the convention of the Declaration of Helsinki. This study protocol was reviewed and approved by the Ethics Committee of the Second Hospital of Jilin University [Approval No.: 2024-026]. Institutional approval was not required to publish the case details.

Acknowledgments

The authors thank the patient for participation in this study and providing written consent for publication.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This work was supported by Jilin Science and Technology Development Program Funded Projects [grant numbers YDZJ202102CXJD074].